Drug Type Small molecule drug |
Synonyms Kaempherol, Robigenin |
Target |
Action agonists, inhibitors |
Mechanism ERs agonists(Estrogen receptors agonists), MARK4 inhibitors(microtubule affinity regulating kinase 4 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC15H10O6 |
InChIKeyIYRMWMYZSQPJKC-UHFFFAOYSA-N |
CAS Registry520-18-3 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Ischemic stroke | Preclinical | China | 01 Aug 2025 | |
| Multiple Sclerosis | Preclinical | China | 01 May 2025 | |
| Multiple Sclerosis | Preclinical | China | 01 May 2025 | |
| Acute myocardial infarction | Preclinical | China | 08 Apr 2025 | |
| Alzheimer Disease | Preclinical | Switzerland | 01 Aug 1999 |





